Title |
Epistemology, Ethics, and Progress in Precision Medicine
|
---|---|
Published in |
Perspectives in Biology & Medicine, January 2016
|
DOI | 10.1353/pbm.2016.0026 |
Pubmed ID | |
Authors |
Spencer Phillips Hey, Brianna Barsanti-Innes |
Abstract |
The emerging paradigm of precision medicine strives to leverage the tools of molecular biology to prospectively tailor treatments to the individual patient. Fundamental to the success of this movement is the discovery and validation of "predictive biomarkers," which are properties of a patient's biological specimens that can be assayed in advance of therapy to inform the treatment decision. Unfortunately, research into biomarkers and diagnostics for precision medicine has fallen well short of expectations. In this essay, we examine the portfolio of research activities into the excision repair cross complement group 1 (ERCC1) gene as a predictive biomarker for precision lung cancer therapy as a case study in elucidating the epistemological and ethical obstacles to developing new precision medicines. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 19 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 6 | 32% |
Student > Ph. D. Student | 2 | 11% |
Student > Bachelor | 1 | 5% |
Student > Master | 1 | 5% |
Unknown | 9 | 47% |
Readers by discipline | Count | As % |
---|---|---|
Philosophy | 2 | 11% |
Arts and Humanities | 2 | 11% |
Medicine and Dentistry | 2 | 11% |
Social Sciences | 1 | 5% |
Computer Science | 1 | 5% |
Other | 2 | 11% |
Unknown | 9 | 47% |